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Acute retinal necrosis (ARN) syndrome is an uncommon
but devastating potentially blinding necrotizing retinitis.
Characteristically presents as a peripheral retinal vasculitis.
It can affect one or both eyes. It is observed most commonly
in healthy patient but occasionally occurs in immunocompro-
mised host.1,2 Most, if not all, cases of ARN syndrome are
caused by infection with a member of the herpes virus family,
usually varicella zoster virus (VZV) or herpes simplex virus
(HSV) type 1 and more rarely by HSV-2 or cytomegalovirus
(CMV).3
The disease is characterized by anterior uveitis, vitritis and
patchy or confluent areas of white- or cream-colored areas of
necrotizing retinitis that rapidly extend posteriorly from the
peripheral retina. Retinal atrophy resulting from necrosis of-
ten leads to secondary rhegmatogenous retinal detachment
(RD). Occlusive vasculitis involves the retinal and choroidal
vasculature.4Current treatment trends vary widely, including single
agents or combination of oral, intravenous, and intravitreal
agents. Differing strategies do not affect outcomes. The final
visual acuity in ARN is generally poor. RD is common and can
neither be predicted nor prevented.
Case report
A 30-year-old white male, previously immunocompro-
mised with AIDS, presented with a 3-week history with
blurred vision, floaters and decreased peripheral vision in
both eyes. He has been under treatment for AIDS for
10 years. His medications included abacavir, lamivudina, lop-
inavir, ritonavir, itraconazole and ganciclovir. His CD4 cell
count was 66/mm3 and viral load was 75.589/mm3.
On examination, the patient’s best visual acuity (BVA)
was 20/50 OU. The intraocular pressure was 14 mmHg and
15 mmHg in the right and left eye, respectively. Fine keratic
precipitates, trace anterior chamber cells, 1+ anteriore:
al.com
13.
244 R.E. Marrocos de Aragão et al.vitreous cells was present in both eyes. Dilated fundus exam-
ination showed retinal arteriolar sheathings in all quadrants,
extensive areas of whitening and retinal necrosis involving
the retina periphery in both eyes (Fig. 1). A diagnosis of bilat-
eral ARN was made, the ganciclovir was changed for intrave-
nous aciclovir for 10 days, and he was prescribed topical
corticosteroids and atropina. One week after the initial pre-
sentation prophylactic laser retinopexy was performed, com-
pletely demarcating involved areas in both eyes (Fig. 2). In
the next two weeks, there was a dramatic resolution of retinal
necrosis resulting in areas of retinal atrophy, his BVA has
improved to 20/30 OU. Patient returned one week later with
complaint about his vision, his BVA was 20/100 in the right
eye and 20/80 in the left eye. On fundus examination retinal
detachment with macula involvement was noted in both
eyes. The patient underwent pars plana vitrectomy, endola-
ser treatment, and silicone oil tamponade. The left eye had
a redetachment, which was surgically repaired in the same
way two weeks later (Fig. 3).
After two months of the initial presentation his BVA was
20/30 in the right eye and 20/200 in the left. His medication
was changed to oral aciclovir 800 mg 5 times daily for
14 weeks. 5 months after the last vitrectomy vision in both
eyes remains stable.
Discussion
Acute retinal necrosis syndrome is an infectious uveitis
usually caused by HSV-1 or -2 or VZV. Features of ARN
syndrome include a vaso occlusive angiitis of both
retinal and choroidal vessels, a necrotizing retinitis thatFigure 1. The arteriolar sheathings in all four quadrants, extensive areas of wh
eyes.preferentially involves the peripheral retina, and significant
intraocular inflammation. Rhegmatogenous retinal detach-
ment is a major late sequela. Urayama et al. first described
ARN syndrome in 1971.4 It has a bimodal age distribution
peaking at approximately 20 and 50 years of age. There is
no clear racial association.6 Although the syndrome was ini-
tially described in healthy patients, it subsequently has been
reported in individuals with compromised systemic immunity,
most notably in those with human immunodeficiency virus
(HIV) infection.7 The ARN syndrome was seen at any level
of HIV infection.8 The ARN syndrome can be insidious or
present with floaters, blurred vision, or rarely decreased
peripheral vision. External examination may reveal diffused
episcleritis, scleritis, or orbital inflammatory disease. Mild to
moderate anterior segment cellular reaction is common.
ARN syndrome is characterized by a retinal vasculitis affect-
ing both the arteries and veins in the fundus, which is mani-
fested by sheathing of the major vessel. Peripheral retinal
whitening is typically present, and the entire peripheral retina
may be involved. Vitritis and optic disk swelling either hyper-
emic or pallid, are common features of the ARN syndrome.
The retinitis may not progress posteriorly to the vascular
arcades, sparing the macula and central vision. Without
treatment, the inflammatory component of ARN syndrome
typically burns out, leaving behind a thin atrophic retina with
pigmentary changes. Rhegmatogenous retinal detachment is
a major cause of visual loss and occurs in 50–75% of cases.
Vitreous traction and proliferative vitreoretinopathy are
complicating factors.7
The diagnosis of ARN syndrome is based on a clinical
examination and a characteristic fundoscopic appearance.itening and retinal necrosis involving the retina periphery for 360 in both
Figure 2. Prophylactic laser retinopexy.
Figure 3. After the pars plana vitrectomy with silicone oil tamponade in both eyes.
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some atypical cases. Differential diagnostic included cyto-
megalovirus retinitis and progressive outer retinal necrosis
(PORN).
Intravenous acyclovir is the current medical treatment of
choice for active ARN syndrome. Initial treatment with a
10 days course of high dose intravenous acyclovir (10 mg/kg
every 8 h) is followed by oral acyclovir (800 mg taken 5 times
a day) for up to 14 weeks. The long-term oral maintenance
therapy may be required in immunosuppressed patients
who develop recurrent lesions. Ganciclovir and foscarnet are
alternative intravenous agents. Intravitreal injections of
ganciclovir or foscarnet may be considered to treat individuals
limited by systemic drug toxicity.7 Anticoagulation to treat
the vascular obstructive component of the ARN syndrome
has been recommended by some investigators.5–7 Systemic
corticosteroids help to control and limit the damage caused
by the severe inflammation associated with ARN syndrome.
Prophylactic laser barrier treatment is recommended at the
earliest opportunity preferably within the first 2 weeks to
reduce the incidence of RD.1
Vitrectomy with silicone oil tamponade is mandatory to
achieve retina reattachment for rhegmatogenous andtraction retinal detachment with multiple retinal tears after
the fulminant type of ARN syndrome.9
Sternberg et al. noted RD in 17% of the eyes treated
prophylactically with laser compared with 67% of un-
treated eyes. Earlier previous reports indicated that only
23% of the detached retinas are successfully reattached,
and only 28% of the eyes affected by ARN syndrome
eventually achieved visual acuities of 20/200 or better.7–10
Our patient achieved the best visual acuity of OD 20/30
and OS 20/200.
The good visual results may be explained by the prompt
diagnosis, proper and early treatment of the complications.
Hillenkamp et al. hypothesized that an intensified therapeutic
approach including early vitrectomy with intravitreal acyclovir
lavage, and, when feasible, laser demarcation of necrotic ret-
inal areas, scleral buckling, and gas or silicon oil tamponade,
may help to halt the progression of the disease, to prevent
secondary RD and phthisis bulbi, and to help to preserve
visual funcion.4 Because the poor prognosis associated with
retinal detachment, prophylactic treatment remains an
important issue.10 The timing of surgical intervention is
crucial to good visual outcome in prophylactic and early vit-
rectomy for acute retinal necrosis.9 Prospective randomized
246 R.E. Marrocos de Aragão et al.clinical trials are need to evaluate the efficacy of the treat-
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